Good morning, Niaz

3 critical alerts · 14 clients with pipeline exposure

March 12, 2026

Drugs Tracked

40

CMS negotiation list

Clients Exposed

14

across 3 coalitions

Revenue at Risk

$8.2B

annual exposure

Active Conflicts

1

access vs. revenue

Recent Changes

View all changes
08:30 · Sec. FDA-2026

FDA Proposes Accelerated Approval Reform — 180-Day Confirmatory Study Mandate

FDA proposed rule requiring confirmatory study initiation within 180 days of accelerated approval and 3-year enrollment completion. Failure triggers expedited withdrawal proceedings.

NationalMedTechRare
06:08 · Sec. CMS-2027

CMS Expands Medicare Drug Price Negotiation List — 30 Additional Drugs

CMS published the final list of 30 additional drugs for Medicare price negotiation under the IRA. 11 National Biopharma Alliance members have products on the expanded list with combined revenue exposure of $8.2B annually.

NationalMedTechRare
14:22 · Sec. SFC-ESOP

Senate Finance Committee Advances ESOP Expansion Bill — 19-7 Vote

Retirement Security Enhancement Act with 25% ESOP tax credit and $50M formation fund advanced with strong bipartisan support. Significant for health sector talent retention.

NationalMedTechRare
09:15 · Sec. HO-AI

House Oversight Committee Launches AI Procurement Investigation

Formal investigation into AI use in federal procurement. Document preservation notices to 15 agencies, subpoenas expected within 72 hours. Focus on algorithmic bias and transparency.

NationalMedTech
16:30 · Sec. Legal

PhRMA Files Constitutional Challenge to IRA Negotiation Framework

PhRMA v. Becerra filed in Delaware federal court challenging the IRA's negotiation framework as unconstitutional taking and compelled speech. Court declined preliminary injunction but case proceeds.

NationalRare

Client Conflict Detected

National Biopharma Alliance and Rare Disease Foundation of America have opposing interests on Section CMS-2027-03Patient Access vs. Manufacturer Revenue — GeneVault Therapy